Technology evaluation: TroVax, Oxford BioMedica.
TroVax, a gene-based tumor vaccine that uses a poxvirus vector to deliver the tumor antigen gene 5T4, is under development by Oxford BioMedica for the potential treatment of cancer. TroVax is undergoing phase II clinical trials.
Reinis
Milan
M
Academy of Sciences of the Czech Republic, Institute of Molecular Genetics, Flemingovo nam 2, Prague 6, CZ 16637, Czech Republic. reinis@img.cas.cz
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D019496:Cancer Vaccines / Q000009:adverse effects* / Q000378:metabolism* / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy; D051379:Mice; D013329:Structure-Activity Relationship; D019444:Vaccines, DNA
D000970:Antineoplastic Agents; D019496:Cancer Vaccines; C504058:TroVax; D019444:Vaccines, DNA